Showing 6141-6150 of 6808 results for "".
- Almirall Completes Investment in Suneva Medicalhttps://practicaldermatology.com/news/almirall-completes-investment-in-suneva-medical/2458900/Barcelona-based Almirall, a global pharmaceutical company, has closed a $15 million in Series C equity investment in Suneva Medical, Inc., marketer of Bellafill®. This product i
- ASDS Skin Cancer Program Honoredhttps://practicaldermatology.com/news/asds-skin-cancer-program-honored/2458901/A skin cancer screening program offered by the American Society for Dermatologic Surgery has been commended with a national 2015 Power of A award for “helping to make the world a better place.” The Choose Skin Health program has been named a Power of A Gold Award winner by the
- Novartis Combination Therapy Tafinlar and Mekinist Receives FDA Priority Review Designationhttps://practicaldermatology.com/news/novartis-combination-therapy-tafinlar-and-mekinist-receive-fda-priority-review-designation/2458904/The FDA has granted priority review for the same patient population for the combination of Novartis’ Tafinlar® (dabrafenib) and Mekinist® (trametinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Also, the Committee for Medi
- Organogenesis Launches PuraPly Wound Management Productshttps://practicaldermatology.com/news/organogenesis-launches-puraply-wound-management-products/2458905/Organogenesis Inc. launched its new PuraPly™ wound management products, including PuraPly Antimicrobial (PuraPly AM), the first FDA-cleared purified collagen matrix with polyhexamethylene biguanide hydrochloride (PHMB) antimicrobial agent. PuraPly and PuraPly AM are the la
- ASDS Finds Age Affects Facial Treatment Preferenceshttps://practicaldermatology.com/news/asds-finds-age-affects-facial-treatment-preferences/2458908/A research-based analysis published in Dermatologic Surgery found that facial treatment preferences among women often are tied to their age. Younger women are more likely to seek cosmetic medical treatments for the upper face while women 50 and older prioritize treatments of the lower fa
- Galderma Receives FDA Approval for Epiduo Forte for Acnehttps://practicaldermatology.com/news/galderma-receives-fda-approval-for-epiduo-forte-for-acne/2458909/The FDA approved Galderma’s antibiotic-free Epiduo® Forte (adapalene and benzoyl peroxide) Gel, 0.3%/2.5%, for the once-daily, topical treatment of acne vulgaris. Epiduo Forte Gel is the first combination of these strengths of the retinoid, adapalene, and benzoyl peroxide, developed for
- Heliocare Earns NSF Good Manufacturing Practice Registration For IFC Manufacturing Facilityhttps://practicaldermatology.com/news/heliocare-earns-nsf-good-manufacturing-practice-registration-for-ifc-manufacturing-facility/2458911/Ferndale Healthcare, Inc.’s IFC manufacturing facility for its Heliocare® brand is now a Good Manufacturing Practices (GMP) facility registered by NSF International, an independent organization recognized as the world leader in standards development, product certification, ed
- LEO Pharma Inc. Announces New Vice President of Saleshttps://practicaldermatology.com/news/leo-pharma-inc-announces-new-vice-president-of-sales/2458915/Mitchell Johnson has joined the LEO U.S. Region as Vice President of Sales. "Mitch is a welcomed addition to our team. He is an energetic sales leader and strategist with proven results in the pharmaceutical industry," stated Barbara Osborne, President & CEO, LEO U.S. Mr. Jo
- DermatologistOnCall Launches New Mobile Apphttps://practicaldermatology.com/news/dermatologistoncall-launches-new-mobile-app/2458919/DermatologistOnCall launched a new mobile app that it says enables patients to quickly and easily start and complete an online visit with a board-certified dermatologist. The app is free and works with Apple's iPhones and iPads, and Android phones and tablets. "Our new mobile app
- Allergan to Acquire Kytherahttps://practicaldermatology.com/news/allergan-to-acquire-kythera/2458927/Allergan has entered into a definitive agreement to acquire Kythera Biopharmaceuticals in a cash and stock transaction valued at $75 per share, or approximately $2.1 billion. Once the transaction is complete, Kythera’s recently approved Kybella (deoxycholic acid) will be part of an aestheti